ENDRA Life Sciences (NASDAQ: NDRA) Advances Treasury Flywheel and TAEUS Registered Liver Imaging Platform

ENDRA Life Sciences (NASDAQ: NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS Registered ) liver imaging technology, is highlighting a powerful new financial engine built through its alignment with the Arca U.S. Treasury Fund (ARCU). The partnership provides ENDRA with an institutional framework to generate reliable yield, preserve capital, and reinvest strategically-strengthening the Company's long-term capacity to advance breakthrough medical innovation.

Company leverages institutional-grade treasury management to generate stable, non-dilutive yield while accelerating development of its next-generation liver imaging technology.

Active Stocks to Watch Now: Q32 Bio Inc (NASDAQ: QBBT), Ambitions Enterprise (NASDAQ: AHMA), Fly-E Group, Inc (NASDAQ: FLYE), and Opendoor Technologies Inc (NASDAQ: OPEN) all active in intraday trading sessions.

A Three-Step Framework That Operationalizes a Financial Flywheel

ARCU employs a disciplined three-step architecture that transforms stable Treasury-based yield into a compounding growth engine:

1. Generate Yield Through Strategic Partnerships

ARCU collaborates with Arca, a leading institutional asset manager overseeing more than $1.5 billion. Through this infrastructure, the fund accesses yield opportunities typically reserved for major financial institutions. By focusing on U.S. Treasury securities and Treasury-backed instruments, ARCU prioritizes capital preservation while generating consistent, predictable returns-an essential pillar for companies seeking non-dilutive growth.

2. Reinvest Under Expert Governance

The reinvestment strategy is guided by Jeff Dorman, Arca's Chief Investment Officer and former Goldman Sachs Managing Director. Dorman ensures Treasury-generated yield is continually reinvested to compound returns while maintaining strict risk controls. This disciplined capital allocation protects against the erosion common in traditional income strategies.

3. Mitigate Risk Through Institutional Controls

ARCU employs real-time portfolio monitoring, liquidity management, and comprehensive regulatory frameworks. The fund diversifies across Treasury maturities and uses defensive positioning when necessary-ensuring the pursuit of yield never compromises capital preservation.

Why This Matters for ENDRA Life Sciences

For ENDRA, ARCU's structure transforms the theoretical concept of a financial flywheel into a fully operational growth engine-producing non-dilutive capital, compounding returns, and reinforcing corporate resilience.

This financial foundation directly fuels the advancement of TAEUS Registered , ENDRA's real-time, non-invasive liver imaging platform designed for measuring liver fat in patients with steatotic liver disease (SLD) and MASH-conditions affecting more than two billion people worldwide.

By integrating institutional-grade treasury management with a groundbreaking medical technology platform, ENDRA is emerging as a leader at the intersection of financial strategy and health innovation. Investors gain exposure to a company combining stable yield generation, disciplined oversight, and a transformative clinical technology positioned for a global market exceeding $100 billion.

ENDRA's model stands as a blueprint for how forward-thinking public companies can leverage modern treasury strategies to power scientific progress, strengthen balance sheets, and build long-term resilience in an evolving capital market environment.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endra-life-sciences-nasdaq-ndra-advances-treasury-flywheel-and-taeus-liver-imaging-platform]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.